You have free access to this content

Cancer

Cover image for Cancer

15 June 2008

Volume 112, Issue 12

Pages 2627–2821

  1. Editorials

    1. Top of page
    2. Editorials
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      Reversible features of cervical cancer in human immunodeficiency virus infection : Impaired access, impaired surveillance, impaired immunity, impaired outcomes (pages 2627–2630)

      Richard F. Little, Andrea M. Denicoff and Edward L. Trimble

      Version of Record online: 21 APR 2008 | DOI: 10.1002/cncr.23499

      Human immunodeficiency virus (HIV)-infected women with cervical cancer appear to have a greater degree of immunosuppression compared with HIV-infected women without cervical cancer. In addition, important issues relevant to health disparities appear to be associated with the risk of cervical cancer.

    2. You have free access to this content
      Should patients consider active surveillance? (pages 2631–2634)

      Peter Albertsen

      Version of Record online: 21 APR 2008 | DOI: 10.1002/cncr.23500

      The aging population, the widespread use of prostate-specific antigen testing, and the introduction of new genetic tests will continue to increase the number of incident cases of localized prostate cancer. Because many of these men harbor low-risk disease, clinicians seriously should consider offering an active surveillance protocol.

  2. Review Article

    1. Top of page
    2. Editorials
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      Targeted therapy in head and neck cancer : State of the art 2007 and review of clinical applications (pages 2635–2645)

      Corey J. Langer

      Version of Record online: 28 APR 2008 | DOI: 10.1002/cncr.23521

      • original image
      • original image

      Recent data confirmed a survival advantage and enhanced locoregional control of squamous cell carcinoma of the head and neck (SCCHN) when cetuximab was added to radiotherapy (RT) in patients with locally advanced (LA) SCCHN. Cetuximab conferred clinical benefits for patients with platinum-refractory/metastatic disease and had an acceptable toxicity profile. A recent phase 3 trial demonstrated a survival benefit when cetuximab was added to standard platinum-based therapy in the front-line treatment of SCCHN.

  3. Original Articles

    1. Top of page
    2. Editorials
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy (pages 2646–2654)

      Jacqueline S. Jeruss, Lisa A. Newman, Gregory D. Ayers, Massimo Cristofanilli, Kristine R. Broglio, Funda Meric-Bernstam, Min Yi, Jennifer F. Waljee, Merrick I. Ross and Kelly K. Hunt

      Version of Record online: 28 APR 2008 | DOI: 10.1002/cncr.23481

      • original image
      • original image
      • original image

      A significant proportion of patients with positive sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy have no positive non-SLNs. In this study, the authors determined that the use of a nomogram based on 5 predictive variables may be useful for predicting the risk of positive non-SLNs in patients with positive SLNs after chemotherapy.

    2. Gastrointestinal Disease
      You have free access to this content
      Hereditary diffuse gastric cancer : Diagnosis, genetic counseling, and prophylactic total gastrectomy (pages 2655–2663)

      Henry T. Lynch, Pardeep Kaurah, Debrah Wirtzfeld, Wendy S. Rubinstein, Scott Weissman, Jane F. Lynch, William Grady, Sara Wiyrick, Janine Senz and David G. Huntsman

      Version of Record online: 28 APR 2008 | DOI: 10.1002/cncr.23501

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Hereditary diffuse gastric cancer is a potentially lethal disorder with limited screening efficacy. In this study, the authors demonstrated that, once it is determined that patients are carriers of a deleterious germline mutation in the type 1 E-cadherin (epithelial) gene (CDH1), they may benefit from prophylactic total gastrectomy.

    3. Genitourinary Disease
      You have free access to this content
      Active surveillance for the management of prostate cancer in a contemporary cohort (pages 2664–2670)

      Marc A. Dall'Era, Badrinath R. Konety, Janet E. Cowan, Katsuto Shinohara, Frank Stauf, Matthew R. Cooperberg, Maxwell V. Meng, Christopher J. Kane, Nanette Perez, Viraj A. Master and Peter R. Carroll

      Version of Record online: 23 APR 2008 | DOI: 10.1002/cncr.23502

      • original image
      • original image

      Selected individuals with early-stage prostate cancer may be candidates for active surveillance. Prostate-specific antigen density at diagnosis and rise in Gleason score on repeat biopsy were found to be associated significantly with the receipt of secondary treatment.

    4. You have free access to this content
      Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802) : A trial of the Eastern Cooperative Oncology Group (pages 2671–2675)

      Robert Dreicer, Hailun Li, Matthew M. Cooney, George Wilding and Bruce J. Roth

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23503

      • original image
      • original image

      A phase 2 trial of combined pemetrexed and gemcitabine was performed in patients with urothelial cancer who were previously untreated for metastatic disease. The 2-agent combination had moderate antitumor activity in these patients at the expense of significant myelosuppression.

    5. You have free access to this content
      Oncofetal protein IMP3 : A novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas (pages 2676–2682)

      Zhong Jiang, Christine M. Lohse, Peigou G. Chu, Chin-Lee Wu, Bruce A. Woda, Kenneth L. Rock and Eugene D. Kwon

      Version of Record online: 15 APR 2008 | DOI: 10.1002/cncr.23484

      • original image
      • original image
      • original image

      IMP3 is an independent prognostic biomarker that can be used to identify a subgroup of patients with localized papillary and chromophobe renal cell carcinoma who are at high risk for developing distant metastasis.

    6. Gynecologic Oncology
      You have free access to this content
      Cervical cancer in patients infected with the human immunodeficiency virus (pages 2683–2689)

      Mario M. Leitao Jr, Paul White and Bernadette Cracchiolo

      Version of Record online: 25 APR 2008 | DOI: 10.1002/cncr.23504

      • original image
      • original image
      • original image

      Women with the human immunodeficiency virus (HIV) who were diagnosed with invasive cervical cancer appeared to have a much greater degree of immunosuppression than women with HIV without invasive cervical cancer.

    7. You have free access to this content
      Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment : Results of Long-Term Follow-up (pages 2690–2697)

      Oliver Zivanovic, Richard R. Barakat, Paul J. Sabbatini, Carol L. Brown, Jason A. Konner, Carol A. Aghajanian, Nadeem R. Abu-Rustum and Douglas A. Levine

      Version of Record online: 21 APR 2008 | DOI: 10.1002/cncr.23485

      • original image
      • original image
      • original image

      Residual disease at the time of second look is the most important prognostic factor for stage IV ovarian cancer patients in first clinical remission.

    8. Head and Neck Disease
      You have free access to this content
      Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck : A case–control study (pages 2698–2709)

      Juliette Thariat, Anesa Ahamad, Adel K. El-Naggar, Michelle D. Williams, Floyd C. Holsinger, Bonnie S. Glisson, Pamela K. Allen, William H. Morrison, Randal S. Weber, K. Kian Ang and Adam S. Garden

      Version of Record online: 21 APR 2008 | DOI: 10.1002/cncr.23486

      • original image
      • original image
      • original image
      • original image
      • original image

      In this case–control study, the authors report that the prognosis for patients with lymph node-positive basaloid squamous cell carcinomas of the head and neck was not worse than that for patients with conventional squamous cell carcinomas.

    9. You have free access to this content
      Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies (pages 2710–2719)

      Jan. B. Vermorken, Roy S. Herbst, Xavier Leon, Nadia Amellal and Jose Baselga

      Version of Record online: 15 MAY 2008 | DOI: 10.1002/cncr.23442

      • original image
      • original image
      • original image

      Efficacy data from studies of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who progressed on platinum-based therapy and subsequently received cetuximab compared favorably with results from a retrospective study of patients who received various other second-line treatments.

    10. Hematologic Malignancies
      You have free access to this content
      Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma : An important variable to be considered in clinical trial designs (pages 2720–2725)

      Bart Barlogie, Jeff Haessler, Mauricio Pineda-Roman, Elias Anaissie, Frits van Rhee, Elias Kiwan, Douglas Steward, Jennifer Gurley, Bonnie Jenkins and John Crowley

      Version of Record online: 23 APR 2008 | DOI: 10.1002/cncr.23487

      • original image
      • original image
      • original image
      • original image

      The clinical impact of completion of premaintenance phases of Total Therapy 2 and 3 protocols for multiple myeloma was investigated using appropriate landmarks. The results revealed that compliance with intended therapies was an independent significant feature associated with prolongation of both event-free and overall survival.

    11. You have free access to this content
      Risk factors for leukemic transformation in patients with primary myelofibrosis (pages 2726–2732)

      Jocelin Huang, Chin-Yang Li, Ruben A. Mesa, Wentling Wu, Curtis A. Hanson, Animesh Pardanani and Ayalew Tefferi

      Version of Record online: 10 APR 2008 | DOI: 10.1002/cncr.23505

      • original image
      • original image

      The current retrospective study of 311 patients with primary myelofibrosis identified a peripheral blood blast percentage of ≥3, a platelet count <100 × 109/L, and treatment history with either erythropoiesis‒stimulating agents or danazol to be independent risk factors for leukemic transformation. The unexpected association between specific therapy and leukemic transformation requires validation by prospective studies.

    12. Hepatobiliary Disease
      You have free access to this content
      Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma : Results of a multicenter phase 2 study (pages 2733–2739)

      Amani Asnacios, Laetitia Fartoux, Olivier Romano, Chloe Tesmoingt, Samy Louafi S, Touraj Mansoubakht, Pascal Artru, Thierry Poynard, Olivier Rosmorduc, Mohamed Hebbar and Julien Taieb

      Version of Record online: 15 APR 2008 | DOI: 10.1002/cncr.23489

      • original image

      In a phase 2 trial of gemcitabine plus oxaliplatin combined with cetuximab in 45 patients with advanced-stage progressive hepatocellular carcinoma, confirmed responses were obtained in 20% of patients and disease stabilization in 40% of patients. The median progression-free and overall survival times were 4.7 and 9.5 months, respectively.

    13. You have free access to this content
      Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor (pages 2740–2748)

      Peng-Yuan Zhuang, Ju-Bo Zhang, Xiao-Dong Zhu, Wei Zhang, Wei-Zhong Wu, Yun-Shan Tan, Jun Hou, Zhao-You Tang, Lun-Xiu Qin and Hui-Chuan Sun

      Version of Record online: 15 APR 2008 | DOI: 10.1002/cncr.23488

      • original image
      • original image
      • original image

      Hepatocellular carcinoma (HCC) with lymph node metastasis (LNM) could be classified into 2 categories based on CK19 expression in tumor: HCC with intrahepatic cholangiocarcinoma (ICC) differentiation (CK19[+]) and higher AJCC/UICC T classification (CK19[−]), and CK19 expression was an independent prognostic factor for HCC with LNM, which has potential for guiding the pertinent treatment modality.

    14. Lung Disease
      You have free access to this content
      Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer (pages 2749–2755)

      David R. Spigel, Ming Lin, Vincent O'Neill and John D. Hainsworth

      Version of Record online: 25 APR 2008 | DOI: 10.1002/cncr.23490

      • original image

      In this open-label, advanced access, phase 3b, erlotinib monotherapy trial in patients with advanced nonsmall cell lung cancer who had previously failed chemotherapy, safety and efficacy results were comparable to the findings from the pivotal phase 3 trial, BR.21. The median duration of survival was 6.3 months (95% confidence interval [95% CI], 4.7–8.0 months), and the best overall response rate was 8.3% (95% CI, 5.2–12.4%). Consistent with previous studies, patients who had never smoked demonstrated a trend toward longer survival and had a higher response rate.

    15. You have free access to this content
      Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer (pages 2756–2764)

      Jinliang Xing, Xifeng Wu, Ara A. Vaporciyan, Margaret R. Spitz and Jian Gu

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23533

      • original image

      By using quantitative real-time polymerase chain reaction, the authors determined messenger RNA expression levels of 3 major double-strand break repair (DSBR) genes—ataxia-telangiectasia mutated (ATM), DNA-dependent protein kinase catalytic subunit (DNA-PKcs), and the Ku heterodimeric regulatory complex 86-kD subunit (Ku80)—in tumor tissues and adjacent normal tissues from 140 patients with nonsmall cell lung cancer. An evaluation of the association between the tumor:normal (T/N) expression ratios of these genes and overall survival demonstrated that expression of ATM and DNA-PKcs, but not of Ku80, was significantly higher in tumor tissues than in normal tissues (P = .003 and P < .001, respectively). Patients with high T/N expression ratios of ATM or DNA-PKcs had notably shorter median survival than patients with low ratios.

    16. You have free access to this content
      Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer (pages 2765–2773)

      Zhong Zheng, Xueli Li, Michael J. Schell, Tingan Chen, David Boulware, Lary Robinson, Eric Sommers and Gerold Bepler

      Version of Record online: 28 APR 2008 | DOI: 10.1002/cncr.23491

      • original image
      • original image
      • original image

      Cytoplasmic expression of thymidylate synthase in nonsmall-cell lung cancer is prognostic of survival. Patients with high levels of tumoral expression live longer than those with low levels of expression.

    17. Sarcoma
      You have free access to this content
      Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy (pages 2774–2779)

      Oren Cahlon, Marnee Spierer, Murray F. Brennan, Samuel Singer and Kaled M. Alektiar

      Version of Record online: 21 APR 2008 | DOI: 10.1002/cncr.23493

      • original image
      • original image
      • original image
      • original image

      This report suggests that select patients with extremity sarcomas who undergo conservative surgery and a pathologically negative re-resection have a low rate of local recurrence to justify omitting the routine use of adjuvant radiation. However, the subset of patients with stage III disease and/or patients ≥50 years old seem to have higher rates of local recurrence and should be considered for adjuvant radiotherapy.

    18. Discipline

      Pathology
      You have free access to this content
      Evidence-based pathology and the pathologic evaluation of thymomas : The World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma (pages 2780–2788)

      Alberto M. Marchevsky, Ruta Gupta, Robert J. McKenna, Mark Wick, Cesar Moran, Maureen F. Zakowski and Saul Suster

      Version of Record online: 28 APR 2008 | DOI: 10.1002/cncr.23492

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The World Health Organization classification of thymomas needs revision and could probably be simplified into fewer classes with significant prognostic value. Evidence-based pathology promotes the use of systematic reviews and analysis of data with meta-analysis rather than subjective reviews of the literature.

    19. Pediatric Oncology
      You have free access to this content
      Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer (pages 2789–2795)

      Javier G. Blanco, Wendy M. Leisenring, Vanessa M. Gonzalez-Covarrubias, Toana I. Kawashima, Stella M. Davies, Mary V. Relling, Leslie L. Robison, Charles A. Sklar, Marilyn Stovall and Smita Bhatia

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23534

      • original image

      The authors examined whether common polymorphisms in the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene CBR3 had an impact on the risk of anthracycline-related congestive heart failure (CHF). Multivariate analyses suggested an association between CBR3 the valine to methionine substitution at position 244 polymorphism and the risk of CHF among childhood cancer survivors.

    20. You have free access to this content
      Disease control intervals in high-risk neuroblastoma (pages 2796–2801)

      Victor M. Santana, Wayne L. Furman, Lisa M. McGregor and Catherine A. Billups

      Version of Record online: 21 APR 2008 | DOI: 10.1002/cncr.23507

      • original image
      • original image
      • original image

      The current study characterized the disease control intervals after diagnosis and subsequent recurrence for 90 patients with disseminated neuroblastoma. The results demonstrated the importance of stratifying for this factor when testing new agents with endpoints based on intervals of disease progression (or control).

    21. Symptom Control and Palliative Care
      You have free access to this content
      Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy : A phase 3 randomized, double-blind, placebo-controlled trial, N01C3 (pages 2802–2808)

      Ravi D. Rao, Patrick J. Flynn, Jeff A. Sloan, Gilbert Y. Wong, Paul Novotny, David B. Johnson, Howard M. Gross, Samer I. Renno, Mohammed Nashawaty and Charles L. Loprinzi

      Version of Record online: 21 APR 2008 | DOI: 10.1002/cncr.23482

      • original image
      • original image
      • original image
      • original image

      Lamotrigine is an antiepileptic agent that has been reported to be effective in reducing the symptoms of neuropathy due to various etiologies. Based on such data, a multicenter, double-blind, placebo-controlled, randomized trial was conducted to evaluate the effect of lamotrigine on pain and other neuropathic symptoms related to chemotherapy-induced peripheral neuropathy.

    22. You have free access to this content
      Preoperative assessment enables the early diagnosis and successful treatment of lymphedema (pages 2809–2819)

      Nicole L. Stout Gergich, Lucinda A. Pfalzer, Charles McGarvey, Barbara Springer, Lynn H. Gerber and Peter Soballe

      Version of Record online: 21 APR 2008 | DOI: 10.1002/cncr.23494

      • original image
      • original image
      • original image
      • original image
      • original image

      There are no standard diagnostic criteria and no agreed upon treatment recommendations for early lymphedema. In this study, the authors demonstrated that a surveillance program was efficacious for detecting and treating early subclinical breast cancer-related lymphedema.

  4. Correspondence

    1. Top of page
    2. Editorials
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content

SEARCH

SEARCH BY CITATION